Investigation of the use of a radioactive dye in the diagnosis of a build-up of protein deposits within the heart

Clinical validation of quantitative flutemetamol PET/CT in cardiac amyloidosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN45011896

Enrollment

Registered

2020-10-02

Start date

2019-08-01

Completion date

Unknown

Last updated

2020-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac amyloidosis including light chain and transthyretin amyloidosis Cancer Cardiomyopathy in metabolic diseases

Interventions

The study aims to validate commercially available positron emission tomography radiotracer Flutemetamol (Vizamyl) to diagnose cardiac amyloidosis. We evaluate the difference in myocardial radiotracer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Previous clinical suspicion of cardiac amyloidosis and currently know the status of their disease (e.g. no amyloidosis, light chain disease, transthyretin)

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Age below 18 years 3. Unknown cardiomyopathy

Design outcomes

Primary

Measure	Time frame
Mortality measured using records from the Finnish national statistical service database at 1, 3 and 5 years	—

Secondary

Measure	Time frame
1. Heart failure measured using patient records diagnoses at 1, 3 and 5 years 2. Heart failure related hospitalizations measured using patient records at 1, 3 and 5 years	—

Countries

Finland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026